statistiche per MACOR, PAOLO

Distribuzione geografica

Continente	#
NA - Nord America	4092
EU - Europa	2865
AS - Asia	315
Continente sconosciuto - Info sul continente non disponibili	9
AF - Africa	3
OC - Oceania	2
SA - Sud America	1
Totale	7287

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	3911
PL - Polonia	1528
IT - Italia	432
UA - Ucraina	245
DE - Germania	208
CA - Canada	181
CN - Cina	157
SE - Svezia	148
GB - Regno Unito	106
TR - Turchia	91
BG - Bulgaria	82
FI - Finlandia	68
VN - Vietnam	36
FR - Francia	19
RU - Federazione Russa	16
EU - Europa	7
IR - Iran	6
IN - India	5
JP - Giappone	5
TW - Taiwan	4
PT - Portogallo	3
RO - Romania	3
SA - Arabia Saudita	3
TN - Tunisia	3
A1 - ???statistics.table.value.countryCode.A1???	2
AU - Australia	2
BD - Bangladesh	2
GR - Grecia	2
HU - Ungheria	2
MY - Malesia	2
NL - Olanda	2
CO - Colombia	1
ES - Italia	1
ID - Indonesia	1
IL - Israele	1
KW - Kuwait	1
SG - Singapore	1
Totale	7287

Salva come PNG Salva come JPEG

Città	#
Warsaw	1528
Woodbridge	644
Fairfield	616
Ann Arbor	516
Houston	352
Wilmington	308
Ashburn	256
Jacksonville	253
Seattle	225
Trieste	204
Cambridge	192
Montréal	151
Mcallen	143
Munich	131
Izmir	88
Sofia	81
Beijing	50
Dearborn	46
San Diego	38
Redmond	37
Dong Ket	35
Falls Church	31
Redwood City	25
Toronto	25
Sacile	19
Düsseldorf	14
Hefei	14
Jinan	13
Milan	12
Nanjing	11
Phoenix	11
Buffalo	10
Norwalk	10
Chicago	9
Rome	8
Udine	8
Kunming	7
Cascina	6
Centro	6
Detroit	6
Padova	6
San Mateo	6
Fuzhou	5
Hebei	5
Palermo	5
Guangzhou	4
Latina	4
Monfalcone	4
Taizhou	4
Tianjin	4
Verona	4
Zhengzhou	4
Clearwater	3
Fremont	3
Hangzhou	3
Indiana	3
Kaohsiung	3
Leawood	3
Madeirã	3
Nanchang	3
North Bergen	3
Saint Louis	3
Shenyang	3
Thuwal	3
Venezia	3
Wuhan	3
Andover	2
Ardabil	2
Arzene	2
Augusta	2
Baotou	2
Changsha	2
Chengdu	2
Courtenay	2
Mestre	2
Mogliano Veneto	2
San Giórgio Di Nogaro	2
Scafati	2
Shanghai	2
Suzhou	2
Taiyuan	2
Adelaide	1
Ankara	1
Arcadia	1
Auburn Hills	1
Azzano Decimo	1
Baltimore	1
Breganze	1
Budapest	1
Caserta	1
Cava	1
Chaoyang	1
Chesapeake	1
Chiba	1
Chongqing	1
Delhi	1
Ferrara	1
Glenside	1
Grafing	1
Hanoi	1
Totale	6285

Salva come PNG Salva come JPEG

Nome	#
Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications	694
Meniscal ossicles as micro-CT imaging biomarker in a rodent model of antigen-induced arthritis: A synchrotron-based x-ray pilot study	301
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers	281
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies	279
Invasive meningococcal disease in three siblings with hereditary deficiency of the 8th component of complement: Evidence for the importance of an early diagnosis	271
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation	269
Targeted delivery of neutralizing anti-C5 antibody to renal endothelium prevents complement- dependent tissue damage	264
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia	222
New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats	204
A non-complement-fixing antibody to 2 glycoprotein I as a novel therapy for antiphospholipid syndrome	186
New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles.	175
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats.	167
null	165
Complement as a biological tool to control tumor growth	160
Targeted nanoparticles and complement activation	141
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.	130
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.	130
null	123
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59	119
null	116
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies.	113
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5	112
Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5.	111
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy	108
Complement as effector system in cancer immunotherapy.	107
Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating	106
Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro.	105
null	104
Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.	102
A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles	101
Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement.	100
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery	99
Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma.	98
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging.	87
Simple scale-up of recombinant antibody production using an UCOE containing vector	82
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.	81
Diagnostic and prognostic role of eEF1A in chronic lymphocytic leukaemia	81
Humoral immunotherapy of multiple myeloma: perspectives and perplexities.	80
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia	78
Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor.	78
The development of atypical hemolytic uremic syndrome depends on complement C5.	77
Alterations in trabecular bone μ-architecture and cartilages in rats with antigen-induced arthritis (AIA) resulting from synchrotron-based X-ray imaging analysis	75
Complement in human diseases: Lessons from complement deficiencies.	75
Complement C1q and C8beta deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illness.	75
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies	71
null	69
Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells	67
P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma.	67
OP0023 Targeted Polymeric Nanoparticles as Diagnostic and Therapeutic Tool for Rheumatoid Arthritis	61
Cubosomes for in vivo fluorescence lifetime imaging	60
High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study	59
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab	56
null	52
null	47
The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis	47
Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis	44
FRI0030 Anti-TNF-α Antibody Targeted To Inflamed Synovial Tissue for The Treatment of Rheumatoid Arthritis	43
Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I	36
The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties	26
The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target	25
The J-elongated conformation of b2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome	23
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination	18
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids	17
Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients	16
An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition	15
Nanoparticles-based oligonucleotides delivery in cancer: Role of zebrafish as animal model	15
Complement system and phagocytosis in a colonial protochordate	14
Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity	12
Hereditary deficiency of the second component of complement: Early diagnosis and 21-year follow-up of a family	11
Totale	7603

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	7603
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	7603

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2016/2017	140	0	0	0	0	0	0	0	0	0	0	0	140
2017/2018	1208	122	202	99	67	47	176	36	240	46	49	85	39
2018/2019	1388	45	49	29	123	72	93	36	91	88	157	378	227
2019/2020	2265	166	163	140	350	190	264	232	205	193	141	142	79
2020/2021	1380	183	100	112	146	118	119	92	105	82	120	66	137
2021/2022	915	90	74	70	88	21	69	38	35	127	98	53	152
Totale													7603

ArTS Archivio della ricerca di Trieste

statistiche per MACOR, PAOLO